Novartis AG · SIX:NOVN
Novartis — Investor Day (January 2005)
15 slides from Novartis's investor day presentation, Jan 20, 2005
Slide 1: Novartis Institutes for BioMedical Research
Novartis Institutes for BioMedical Research Mark C. Fishman, MD President Novartis Institutes for BioMedical Research The Great Challenge to Pharmaceutical Discovery Why are there so few new drugs per year (~20), a minority of which address truly novel targets? 2 FRESCO 2004 / Mark Fishman / 2005-01
Slide 2: The Great Challenge to Pharmaceutical Discovery
The Great Challenge to Pharmaceutical Discovery Translational The mechanisms of many diseases are insufficiently understood to choose valid drug medicine targets New grammar for target The genome has not been functionalized in a manner to expedite discovery discovery Expand the The chemical universe
Slide 3: Meeting the Challenge at NIBR – New Programs
Meeting the Challenge at NIBR – New Programs • Proof-of-Concept trials Translational • Patient stratification medicine • Clinical science integration • Novel molecular pathway approaches New grammar • New in vivo genetic models for target • Expanded genome mining discovery • Systems biology • Increa
Slide 4: Metabolic Syndrome
Metabolic Syndrome Dyslipidemia Diabetes Obesity Atherosclerosis 24% of the US population has metabolic syndrome 7 FRESCO 2004 / Mark Fishman / 2005-01-20 / Analysts Metabolic Syndrome PPAR1 Receptors as Drug Targets Dyslipidemia Diabetes Obesity PPARα PPARγ (fibrates) fibrates) (TZDs2) Atherosclero
Slide 5: Metabolic Syndrome – LBM642, a Dual PPARα and PPARγ Agonist
Metabolic Syndrome – LBM642, a Dual PPARα and PPARγ Agonist • LBM642 is A novel pharmacophore designed by computer-aided molecular modelling as an agonist for PPARα and PPARγ receptors • In rodent models, LBM642 improves lipid profile and insulin resistance, without fat accumulation or increase in b
Slide 6: LBM642 Treatment Improves Atherogenic Profile
Metabolic Syndrome LBM642 Treatment Improves Atherogenic Profile Day 29 cholesterol (mg / dL): % change from baseline1 Atherogenic LDL 10 Fenofibrate 160 mg 0 (n=9) LBM642 2 mg (n=8) -10 -20 -30 35 31 17 11 6 1 1 Interim results Fractions 11 FRESCO 2004 / Mark Fishman / 2005-01-20 / Analysts Metabol
Slide 7: Treatment-refractory Chronic Myeloid Leukemia – An Unmet Medical Need
Three Examples of Proof of Concept Trials for Unmet Medical Needs 1. Metabolic syndrome and diabetes: LBM642 2. Chronic myeloid leukemia (CML) resistant to Glivec®1 : AMN107 3. Relapsing multiple sclerosis: FTY720 1 Gleevec® in US 13 FRESCO 2004 / Mark Fishman / 2005-01-20 / Analysts Treatment-refra
Slide 8: CML – AMN107, a Highly Selective and Potent BCR-ABL Inhibitor
CML – AMN107, a Highly Selective and Potent BCR-ABL Inhibitor Glivec® • AMN107 is a small molecule tyrosine kinase inhibitor designed to optimize interaction with the ATP-binding pocket of BCR-ABL • It is the most selective BCR-ABL inhibitor tested to date • It is more potent than Glivec® on recepto
Slide 9: CML – Conclusions for AMN107
CML – Conclusions for AMN107 • In preclinical studies, AMN107 is the most potent and selective BCR-ABL inhibitor examined, and is active against most of the common BCR-ABL mutations (all examined except for T315I) • AMN 107 is well tolerated up to 1200 mg daily (rare liver, skin, marrow AEs) AMN107
Slide 10: Multiple Sclerosis
Multiple Sclerosis • Chronic inflammatory disease of central nervous system • One of the most common causes of disability in adults of working age − Prevalence 1.1 m worldwide − 50% wheelchair-bound 15 years after diagnosis Brain areas affected by MS 19 FRESCO 2004 / Mark Fishman / 2005-01-20 / Anal
Slide 11: FTY720, an Oral Immunomodulatory Compound
Multiple Sclerosis FTY720, an Oral Immunomodulatory Compound • FTY720 causes sequestration of T lymphocytes in lymph nodes • FTY720 effectively treats animal model of MS Lymph Nodes PoC Trial: • Double-blind, placebo-controlled, randomized study • 281 patient with relapsing MS treated for 6 months (
Slide 12: 2004 In-licensed Compounds Complement Preclinical Pipeline
Conclusion for FTY720 in Multiple Sclerosis FTY720 has the potential to be the first oral agent for disease modification in multiple sclerosis 23 FRESCO 2004 / Mark Fishman / 2005-01-20 / Analysts 2004 In-licensed Compounds Complement Preclinical Pipeline SCD-1 inhibitor, metabolic syndrome (Xenon)
Slide 13: 2004 Collaborations Established to Drive Preclinical Drug Discovery
2004 Collaborations Established to Drive Preclinical Drug Discovery Molecular Pathways (Cellzome) Therapeutic antibodies (Morphosys AG) Novel chemistry platform (Infinity Pharmaceuticals) Type 2 diabetes genetics (Broad Institute of MIT and Harvard) 25 FRESCO 2004 / Mark Fishman / 2005-01-20 / Analy
Slide 14: Anticipated Upcoming PoC Trials Cover Broad Spectrum of Unmet Medical Need
Meeting the Challenge at NIBR – New Programs • Proof-of-Concept trials Translational • Patient stratification medicine • Clinical science integration • Novel molecular pathway approaches New grammar • New in vivo genetic models for target • Expanded genome mining discovery • Systems biology • Increa
Slide 15: A Renaissance in Drug Discovery is Underway
Conclusion A Renaissance in Drug Discovery is Underway Translational Proof of concept trials – and translational medicine – focus drug discovery upon medicine tractable problems New grammar for target The human genome can provide a new grammar for drug discovery discovery Expand the The universe of